Attached files

file filename
EX-99.1 - Microbot Medical Inc.ex99-1.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): March 29, 2017

 

MICROBOT MEDICAL INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   000-19871   94-3078125

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

5 Hamada Street

Yokneam 2069204 Israel

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (908) 938-5561

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

Item7.01 Regulation FD Disclosure

 

On March 29, 2017, Microbot Medical Inc. (the “Registrant”) issued a press release announcing that it will host an investor briefing conference call and webcast on Thursday, April 6, 2017, at 10:00 a.m., Eastern time.

 

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

  Exhibit No.   Description
       
  99.1   Press Release

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MICROBOT MEDICAL INC.
     
  By:

/s/ Harel Gadot

  Name: 

Harel Gadot

  Title:

Chairman, President and Chief Executive Officer

 

Date: March 29, 2017